Is Corbus Pharmaceuticals Holdings, Inc. overvalued or undervalued?

As of 8 March 2022, the valuation grade for Corbus Pharmaceuticals Holdings, Inc. moved from risky to does not qualify, indicating a significant change in its perceived investment quality. The company is currently considered overvalued given its financial metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 0.89, and the EV to EBITDA is at 0.32, suggesting that the market may not be accurately pricing the company's potential.
In comparison to its peers, Corbus Pharmaceuticals shows a stark contrast with ASP Isotopes, Inc. and ARCA biopharma, Inc., which have P/E ratios of -24.0140 and -5.3909, respectively. This places Corbus in a challenging position within its industry, where other companies are also struggling. The company's recent stock performance has been notably poor, with a year-to-date return of -33.14%, significantly underperforming the S&P 500's 2.44% return. Overall, the combination of these factors leads to the conclusion that Corbus Pharmaceuticals is overvalued in the current market environment.